Long‐term efficacy and safety of oxycodone‐naloxone prolonged‐release formulation (up to 180/90 mg daily) – results of the open‐label extension phase of a phase III multicenter, multiple‐dose, randomized, controlled study
European Journal of Pain2017Vol. 21(9), pp. 1485–1494
Citations Over TimeTop 10% of 2017 papers
Denis Dupoiron, Andrzej Stachowiak, O. Loewenstein, Adam Ellery, Walter K. Kremers, B. Bosse, Michael Hopp
Abstract
In patients with pain requiring continuous opioid therapy at doses above 80 mg of oxycodone, stable and effective long-term analgesia can be achieved using OXN PR up to 180/90 mg daily without compromising bowel function and may be preferential to supplemental oxycodone.
Related Papers
- → Opioid Concentrations in Oral Fluid and Plasma in Cancer Patients With Pain(2014)37 cited
- → Analgesic Concentrations of Oxycodone – A Prospective Clinical PK/PD Study in Patients with Laparoscopic Cholecystectomy(2011)48 cited
- Efficacy of oxycodone-acetaminophen as an adjuvant of opioid analgesics for cancer pain(2009)
- → Survival on controlled-release morphine versus controlled-release oxycodone in opioid-naïve patients with non-malignant pain: data from Danish national health registers(2013)
- Opioid Concentrations in Oral Fluid and Plasma in Cancer Patients With Pain(2015)